Iovance Biotherapeutics Q3 2026 Earnings Date & Estimates

Iovance Biotherapeutics (NASDAQ:IOVA) is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company’s platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy. Treatment involves collecting tumor tissue, expanding the patient’s TILs, administering a lymphodepleting chemotherapy regimen and reinfusing the expanded cells, followed by supportive interleukin-2 therapy.

The company is also evaluating TIL-based therapies in additional solid tumors and cancer-treatment settings, including combination approaches designed to broaden the potential use of its cell therapy platform. Iovance, formerly known as Lion Biotechnologies, changed its name in 2017 and is headquartered in San Carlos, California. Its commercial activities are centered in the United States, while its development programs have involved clinical research conducted across multiple regions.